^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) + OTS514 (TOPK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KRASG12C mutation-induced TOPK overexpression contributes to tumour progression in non-small cell lung cancer
Published date:
05/24/2023
Excerpt:
To further evaluate the anticancer potential of the combination of OTS514, AMG510 and 5-FU, we treated KRASG12C A549 cells with different combination of drugs and examined the cell death and proliferation…when the three agents were applied together (5-FU + OTS514 + AMG510), an even stronger apoptosis induction and anti-proliferation effects were observed (Figure 8A–C). Therefore, the combinatory usage of 5-FU, OTS514 and AMG510 could potentially produce the optimal anticancer effect against NSCLC with KRASG12C mutation.
Secondary therapy:
5-fluorouracil
DOI:
https://doi.org/10.1111/jcmm.17640
